Stockwinners Market Radar for May 08, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Translate Bio Inc. trading halted, news pending

19:01 EDT Sunrun sees FY24 Storage Capacity Installed up 40%-75% - The company stated: "Storage Capacity Installed is expected to be in a range of 800 to 1,000 Megawatt hours the full-year 2024. This range represents approximately 40% to 75% growth year over year. Storage Capacity Installed is expected to be in a range of 215 to 225 Megawatt hours in the second quarter of 2024. This range represents approximately 105% to 115% growth year over year. Solar Energy Capacity Installed is expected to be in a range reflecting a decline of 15% to flat growth for the full-year 2024, a reduction from our prior guidance range of -5% to +5% growth. Solar Energy Capacity Installed is expected to be in a range of 190 to 200 Megawatts in the second quarter of 2024."

18:26 EDT Corsair Gaming pursuing acquisition of Fanatec - The company states: "CORSAIR announced that it has entered exclusive negotiations to acquire sim racing specialist Endor AG, owners of the world famous Fanatec brand. CORSAIR has reached an agreement with Endor to fund its short-term cash needs while both companies negotiate a restructuring of Endor's approximately EUR 70 million of debt, which will ultimately result in CORSAIR acquiring Endor. Endor is a leading manufacturer of dedicated sim racing hardware, including force feedback steering wheels, pedals, and complete cockpits for PlayStation, Xbox, and PC-based racing simulators. This acquisition bolsters the investment CORSAIR has made in the simulation space, and means it is uniquely positioned going forward to provide peerless sim racing solutions."

18:12 EDT Houlihan Lokey raises quarterly dividend to 57c per share from 55c - The dividend will be payable on June 15, 2024 to stockholders of record as of the close of business on June 3, 2024.

18:03 EDT Costco reports April comparable sales up 5.6% - Reports April revenue of $19.8B, up 7.1%. Reports April e-commerce sales up 14.6%.

17:57 EDT Crescent Capital BDC increases quarterly dividend to 42c per share - The company increased its regular quarterly cash dividend by 1c to 42c per share. The company's board declared the regular cash dividend of 42c per share to stockholders of record as of June 28, payable on July 15. The board also announced a first quarter 2024 supplemental cash dividend of 11c per share to stockholders of record as of May 31, payable on June 17.

17:41 EDT Jones Soda, Street League Skateboarding enter multi-year partnership - Street League Skateboarding and Jones Soda Co. "announced a multi-year partnership to champion current and future generations of action sports. Jones Soda., a longtime supporter of skateboarding and other action sports, will now join forces with the world's largest competitive skateboarding league to amplify the SLS community and innovative spirit of SLS events. The partnership will feature an integration of the Jones Soda Co. product and the brand's own action sports heritage into SLS venues, SLS athlete activations, content, and branding throughout the 2024 and 2025 SLS seasons. Through the partnership, Jones will also serve as the official sponsor of SLS Futures, the league's all-new youth development program. Jones' beverages will be featured across the calendar of SLS events in 2024 and 2025 beginning with the league's upcoming SLS Apex on May 25, providing fans the opportunity to enjoy an exciting array of craft sodas as the world's best skateboarders compete at the highest levels in search of the SLS Super Crown title. SLS athletes and brand influencers will also be given the opportunity to engage with Jones Soda Co. as the league's latest brand partner, further building on the shared community-first spirit of SLS and Jones."

17:35 EDT Mind Medicine discloses CFO transition - The company states: "On May 3, 2024, the Company made a transition in the role of Chief Financial Officer resulting in the departure of Schond Greenway. MindMed has retained an executive search firm to assist in identifying a new Chief Financial Officer."

17:18 EDT Hecla Mining affirms 3-year production outlook - The Company is reiterating its three-year production outlook and 2024 cost and capital guidance.

17:14 EDT Watts Water narrows FY24 organic sales outlook to down 4% to up 1% - Prior guidance was down 5% to up 1%. Raises FY24 adjusted EBITDA margin view to 19.6%-20.2% from 19.4%-20%. Raises FY24 adjusted operating margin view to $17.1%-17.7% from 16.9%-17.5%. Reference Link

17:10 EDT F&G Annuities reaches $5B in cumulative pension risk transfer sales - F&G Annuities announced cumulative sales of pension risk transfer - PRT - transactions of over $5B since the channel was launched in June 2021. Since its inception nearly three years ago, the company's PRT channel, one of F&G's institutional markets, now includes more than 100,000 total participants, including beneficiaries, who will receive their pension payments from F&G.

17:02 EDT Trinseo sees Q2 adjusted EBITDA $60M-$75M - Sees Second quarter 2024 net loss of $53 million to $38 million. Commenting on the second quarter outlook, Frank Bozich, President and Chief Executive Officer of Trinseo said, "We are seeing the positive earnings momentum from the end of the first quarter continue into the second quarter, including similar sales and margin levels to start the quarter. I am confident in a significant sequential profitability improvement as the turnaround at Americas Styrenics is behind us, and as we enter the seasonally stronger period for many of our building and construction applications. Additionally, there has been continued tightness in the styrene and MMA markets that is supportive of continued higher margins. We also expect a sequential free cash flow improvement from higher profitability and moderating styrene prices."

16:57 EDT BG Staffing announces review of strategic alternatives, dividend suspension - BGSF announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives and has engaged Houlihan Lokey as its financial advisors in this endeavor to maximize shareholder value, and the Company has also suspended its quarterly cash dividend until this strategic review is complete.

16:51 EDT Rand Capital raises quarterly dividend 16% to 29c per share - The dividend will be distributed on or about June 14, 2024, to shareholders of record as of May 31, 2024.

16:47 EDT Watts Water increases quarterly dividend by 19% - The company announced a 19% increase in quarterly dividend payments, increasing the quarterly payments to 43c per share from 36c per share beginning in June 2024.

16:45 EDT Kennedy Wilson cuts quarterly dividend to 12c per share - Kennedy Wilson announced that the company will pay a dividend of 12c per share or 48c per share annually to common shareholders of record as of June 28, 2024, with a payment date of July 5, 2024. The resized dividend rate will allow the company to retain $66M per year, strengthening the company's ability to grow its investment management business, repurchase securities, and reduce leverage.

16:28 EDT Anika Therapeutics announces CFO transition - Anika Therapeutics announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve is an accomplished public company leader whose ability to connect strategic, operational, and financial expertise will be a significant asset for our Company. I am confident that Steve will build on our recent momentum and partner with our operating teams to achieve the meaningful value building potential across the business."

16:27 EDT P3 Health Partners names Dr. Aric Coffman as CEO - P3 Health Partners named Dr. Aric Coffman as P3's Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3's Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company's Board of Directors working closely with Dr. Coffman to ensure a smooth transition. Dr. Coffman is an exceptional physician leader with a proven track record of success in the value-based care sector, most recently as the CEO of Honest Medical Group, a Rubicon Founders portfolio company. He brings over two decades of experience in leading provider organizations in delivering high quality, highly efficient healthcare delivery for seniors in the Medicare Advantage and ACO market. Prior to his tenure at Honest, Dr. Coffman was the CEO of the Everett Clinic and Northwest Physicians Network (Part of OptumCare) where he doubled MA membership and led them into the full risk DSNP market segment.

16:25 EDT Enhabit: Determined continuing as independent company is in best interests

16:25 EDT Myomo expects 'better line of sight' into FY24 forecast in Q2 - "Given our backlog, we're in a position to generate more than $5.0 million in product revenue in the second quarter," said Paul Gudonis, Myomo's chairman and chief executive officer. "We're making progress on our capacity expansion plans, hiring approximately 20 people during the first quarter. We have the opportunity to generate between $28 million and $30 million in revenue in 2024, presuming that we meet our hiring goals and that there are no supply chain or other unexpected disruptions. We expect to have a better line of sight into this forecast by the time we report our second quarter financial results. We continue to believe that reaching operating cash flow breakeven on a quarterly basis by the fourth quarter of 2024 is achievable."

16:24 EDT Enhabit concludes review of strategic alternatives - Enhabit announced Enhabit's Board of Directors has concluded the Company's strategic review process, announced in August 2023, which was overseen by the Board with assistance from its financial and legal advisors, Goldman Sachs and Sidley Austin, respectively. After evaluating a full range of strategic alternatives, including a potential sale, merger or other transaction, the Board unanimously determined that continuing to execute on the Company's strategic plan as an independent, public company is in the best interests of the Company and its shareholders at this time. The Company and its advisors ran a thorough strategic review process that concentrated on a merger or acquisition of the Company. The Board directed the Company's financial advisor to identify potential strategic partners and financial sponsors that might be interested in an acquisition of or strategic combination with the Company. In addition to inbound inquiries, outreach was conducted to a comprehensive range of strategic and financial counterparties. The Company executed Non-Disclosure Agreements with a broad number of counterparties and received indications of interest from a variety of counterparties. There was serious interest based on parties' engagement in the process; however, the Company did not receive any formal proposals for a transaction. "We believe macro headwinds including, among other things, uncertain regulatory developments including Medicare reimbursement policies throughout the healthcare industry and an evolving antitrust landscape, a difficult healthcare operating environment, and persistently high interest rates ultimately stifled possibilities for a transaction that would enhance shareholder value," said Chairperson of the Board Leo Higdon. "Considering this, and other strategic alternatives reviewed with advisors during the review process, the Board determined the best way to enhance shareholder value at this time is to continue to operate as a stand-alone business. The Board looks forward to working with the management team to lead the Company's execution on its operating plan. The Board remains committed to enhancing value for all shareholders and will continue to be open to and evaluate all opportunities to do so." The Board and management team remain focused on the Company's financial and operating results. "With the strategic alternatives review process concluded, the management team is focused on operating Enhabit's core businesses," said President and Chief Executive Officer Barbara Jacobsmeyer. "Our momentum exiting 2023 and through the first quarter of 2024, in which we hired additional frontline clinicians, negotiated more and better home health payor contracts, and controlled G&A expenses, instills excitement in our strategy and team, and we are confident we are taking the right steps to drive future growth to increase shareholder value."

16:20 EDT Regenxbio sees cash, cash equivalents, securities sufficient into 2026 - Expects its balance in cash, cash equivalents and marketable securities of $380.5M as of March 31, 2024 to fund its operations into 2026. This cash runway guidance is based on the company's current operational plans and excludes the impact of any payments that may be received from AbbVie upon the achievement of development or commercial milestones under the ABBV-RGX-314 collaboration, including a potential, one-time $200.0M milestone for achievement of first patient dosed in the first pivotal trial for suprachoroidal delivery for treatment of DR, and the potential monetization of a priority review voucher that may be received for RGX-121.

16:17 EDT Acadia Pharmaceuticals sees FY24 NUPLAZID net sales $560M-$590M - Acadia is reiterating all of its 2024 guidance provided on February 27, 2024. DAYBUE net product sales guidance in the range of $370 to $420 million. R&D expense in the range of $305 to $325 million. SG&A expense in the range of $455 to $480 million.

16:12 EDT Mirum Pharmaceuticals announces H1 milestones on track - Regulatory and Pipeline: H1 Milestones on track: Interim analyses for volixibat in PSC and in PBC expected in June of 2024. New Drug Application submission for CHENODAL in CTX on track for first half 2024. PFIC CHMP approval recommendation anticipated in the first half of 2024

16:10 EDT Robinhood sees 2024 expenses $1.85B-$1.95B - The company said: "Our 2024 expense plan includes growth investments in new products, features, and international expansion while also getting more efficient in our existing businesses. Taken together, we continue to expect both GAAP total operating expenses and Non-GAAP combined Adjusted Operating Expenses and SBC for full-year 2024 to be in the range of $1.85 billion to $1.95 billion."

16:08 EDT VSE Corp. names Tarang Sharma as interim CFO - VSE Corporation announced the appointment of Tarang Sharma to interim Chief Financial Officer effective May 27, 2024. Mr. Sharma, VSE's Vice President, Controller and Corporate Development, succeeds Steve Griffin, who is departing the Company to pursue an opportunity outside of the Aerospace industry. VSE has initiated a search for a CFO with the assistance of an executive search firm.

15:13 EDT Zscaler says aware of threat actor claim of obtaining unauthorized information - Zscaler stated in a security update: "Zscaler is aware of a public X (formerly known as Twitter) post by a threat actor claiming to have potentially obtained unauthorized information from a cybersecurity company. There is an ongoing investigation we initiated immediately after learning about the claims. We take every potential threat and claim very seriously and will continue our rigorous investigation. We will continue to investigate, monitor the situation and provide an update." Reference Link

14:02 EDT Chesapeake Utilities raises dividend to 64c per share - The board of directors of Chesapeake Utilities voted to increase the quarterly cash dividend on the company's common stock from 59c per share to 64c per share, which raises the 2024 annualized dividend by 20c from $2.36 to $2.56 per share, an 8.5% increase. The 64c per share dividend will be payable July 5 to all shareholders of record at the close of business on June 14.

12:35 EDT ServiceNow announces expansion of relationship with Equinix - At ServiceNow's (NOW) annual customer and partner event, Knowledge 2024, ServiceNow announced an expansion of the strategic relationship with Equinix (EQIX) to streamline operations of digital infrastructure. The proposed new offerings ServiceNow and Equinix plan to develop are intended to give end-to-end visibility and intelligent insights across the entire enterprise IT stack, including data center infrastructure through ServiceNow's AI-first platform, ServiceNow said. The ServiceNow - Equinix offerings are expected to be available to customers in early 2025.

12:33 EDT ServiceNow announces collaboration agreement with IBM - At ServiceNow's (NOW) annual customer and partner event, Knowledge 2024, ServiceNow announced a collaboration with IBM (IBM) to accelerate the impact of generative AI across the enterprise. Service Now said that a new integration will combine the power of the Now Platform with IBM watsonx to boost productivity for mutual customers and partners. ServiceNow will also incorporate watsonx.ai and IBM Granite foundation large language models into its Now Assist GenAI experience for ServiceNow customers.

12:17 EDT Mattel names Karen Ancira EVP, chief people officer - Mattel (MAT) announced that Karen Ancira has been appointed Executive Vice President and Chief People Officer for the company, effective May 15. Ancira will report to Ynon Kreiz, Chairman and CEO of Mattel. Kreiz said: "Karen is an exceptional leader with a proven track record of cultivating purpose-driven, values-based Human Resources organizations and programs for major consumer brands globally. We look forward to the impact Karen will make to further inspire and engage our high-performing and collaborative workforce at Mattel." Joining Mattel following 11 years with Yum! Brands (YUM), Ancira was most recently Chief People and Culture Officer, KFC, US.

12:01 EDT Enerflex falls -19.5% - Enerflex is down -19.5%, or -$1.19 to $4.92.

12:00 EDT DoubleVerify falls -39.3% - DoubleVerify is down -39.3%, or -$12.00 to $18.57.

12:00 EDT Kyndryl Holdings rises 24.0% - Kyndryl Holdings is up 24.0%, or $4.98 to $25.75.

10:54 EDT Marshall & Ilsley Corporation trading resumes

10:49 EDT Marshall & Ilsley Corporation trading halted, volatility trading pause

10:34 EDT Cazoo says notices of intention to appoint administrators filed with High Court - In a regulatory filing, Cazoo disclosed: "In accordance with the requirements under paragraph 26 of Schedule B1 of the UK Insolvency Act 1986 and rule 3.23 of the Insolvency Rules 2016, on May 8, 2024, notices of intention to appoint administrators were filed with the English High Court in respect of certain of the material subsidiaries of Cazoo Group Ltd that are incorporated in England: (i) Cazoo Holdings Limited, a subsidiary of the Company and a holding company with no material assets other than an ownership interest in our subsidiaries, (ii) Cazoo Ltd, our operating subsidiary through which our operations, including our marketplace business, are conducted, and (iii) Cazoo Properties Limited, our subsidiary that owns the majority of our leaseholds. On receipt of each notice by the Court, an interim moratorium commenced in respect of each Subsidiary as a result of which creditors of each Subsidiary are generally prohibited from taking action to enforce their debts against each Subsidiary and its assets without the permission of the Court. The interim moratorium lasts until administrators are appointed (at which point the administration moratorium becomes effective), or ten business days expires without administrators having been appointed. Notwithstanding the aforementioned filings, the Subsidiaries will continue to operate in the ordinary course of business. As disclosed on May 1, 2024, if certain of the Company's operating subsidiaries file for administration or liquidation, we would need to consider the best options for the Company at such time. The options may include filing for administration or winding up the Company."

10:03 EDT IBM, SAP plan to expand collaboration around generative AI - IBM (IBM) and SAP SE (SAP) announced "their vision for the next era of their collaboration, which includes new generative AI capabilities and industry-specific cloud solutions that can help clients unlock business value." Scott Russell, Chief Revenue Officer and Executive Board Member, Customer Success of SAP SE, said: "It makes perfect sense to expand our partnership with IBM to help more customers accelerate their cloud journey leveraging RISE with SAP and realize the transformative benefits of generative AI for business in the cloud. This expanded partnership will help more of our joint customers reach new heights by innovating through the cloud, data and business AI to grow and transform their businesses."

10:03 EDT First Merchants announces retirement of board chair Charles Schalliol - First Merchants Corporation announced that Jean L. Wojtowicz has been appointed as First Merchants Corporation and First Merchants Bank Chair of the Board of Directors. Effective May 7, Wojtowicz succeeds Charles E. Schalliol, who retired after serving as Chair for the past seventeen years. Schalliol said, "It has been my pleasure to serve as Chair of the Board of First Merchants for the past 17 years during which time First Merchants has enjoyed unprecedented success. I am confident that Jean will do an excellent job building on that success." Additionally, Michael C. Rechin, former First Merchants Corporation CEO, was appointed as Vice Chair of the Board of Directors effective May 7.

10:01 EDT Connection unit awarded Federal Purchase Agreement worth $125M - Connection (CNXN) is pleased to announce that its public sector subsidiary, Connection Public Sector Solutions, has been awarded a Blanket Purchase Agreement for the Administrative Office of the U.S. Courts and the Federal Judiciary. The single award Blanket Purchase Agreement covers the purchase of specific Microsoft (MSFT) products and ancillary services in support of IT systems and other IT requirements-and has an estimated value of $125M in total. The BPA has a base period of three years, with one three-year option extending coverage through November 2029. The BPA is open for ordering by all judiciary organizations and their authorized contracting officers or ordering officials.

10:01 EDT Inspire Medical falls -28.9% - Inspire Medical is down -28.9%, or -$70.96 to $174.67.

10:00 EDT Elanco rises 21.6% - Elanco is up 21.6%, or $2.92 to $16.44.

10:00 EDT PowerSchool rises 24.3% - PowerSchool is up 24.3%, or $4.04 to $20.68.

09:48 EDT Inspire Medical falls -25.5% - Inspire Medical is down -25.5%, or -$62.63 to $183.00.

09:47 EDT Globus Medical rises 15.8% - Globus Medical is up 15.8%, or $8.13 to $59.49.

09:47 EDT PowerSchool rises 25.9% - PowerSchool is up 25.9%, or $4.31 to $20.95.

09:41 EDT Quanterix trading halted, volatility trading pause

09:40 EDT TripAdvisor trading resumes

09:35 EDT TripAdvisor trading halted, volatility trading pause

09:30 EDT Natures Sunshine Products trading halted, volatility trading pause

09:20 EDT Vintage Wine Estates amends the amended forbearance agreement - Vintage Wine Estates announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, as amended, the "amended forbearance agreement", to extend the forbearance period to June 4. The lenders have also agreed to defer the $10M principal payment previously due at May 15 to June 17 Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, so long as the Company complies with the terms of the amended forbearance agreement and otherwise remains in compliance with the Second Amended and Restated Loan and Security Agreement.

09:18 EDT CEL-SCI gets FDA approval to move forward with Multikine study - CEL-SCI announced an outcome from its recent meeting with the FDA regarding the path to approval for its first-line investigational cancer immunotherapy Multikine. Based on strong safety and efficacy data from CEL-SCI's completed Phase 3 head and neck cancer study, the FDA indicated CEL-SCI may move forward with a confirmatory Registration Study of Multikine in newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression.

09:16 EDT CuriosityStream reports Peter Westley will resign as CFO, Hayden to succeed - Last night, CuriosityStream announced a transition among its executive leadership. Peter Westley will resign his role as Chief Financial Officer and return to consulting status with the company effective May 31. "Westley helped shepherd CuriosityStream to positive cash flow, oversaw distribution of the Company's first dividend and built a capable Finance team, including Controller Brady Hayden. The Board of Directors has named Hayden, who held previous positions with Cyren Ltd, US Postal Service and Spok Holdings Inc., CFO effective May 31," the company stated.

09:10 EDT NI Holdings agrees to sell Westminster American Insurance for $10.5M in cash - NI Holdings announced an agreement to sell its wholly-owned commercial insurance subsidiary, Westminster American Insurance Company, to a private party. The total consideration for the sale is $10.5 million in cash, with proceeds planned to be used for general corporate purposes. The transaction was unanimously approved by the Board of Directors and is expected to close in 2024, subject to regulatory approval and other closing conditions. "The decision to sell Westminster American Insurance Company was made in the best interest of NI Holdings and its shareholders," said Michael J. Alexander, President, and Chief Executive Officer. "The commercial habitational insurance market has undergone significant changes in recent years, which were largely the result of unforeseen circumstances including the COVID-19 pandemic, the persistent high inflationary environment, tort liability rulings in certain states, and the challenging property reinsurance market. Given these changes, we believe this market no longer aligns with the strategic direction of NI Holdings. This sale will allow us to refocus resources to our core businesses, which we believe will help NI Holdings deliver appropriate returns over time."

09:08 EDT Alpha Pro Tech reports Q1 EPS 5c vs 5c last year - Reports Q1 revenue $13.48M vs $13.8M last year. Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, "The Building Supply segment continues to show strength, as it achieved 7.6% growth on its core building products in the first quarter of 2024, as compared to the same period of 2023. This was accomplished even though there continues to be economic uncertainty in the housing market due to inflation, high interest rates and historical volatility during election years.

09:06 EDT Xperi shareholder Rubric urges stockholders to vote for their board nominees - Rubric, an investment advisor whose managed funds and accounts collectively own approximately 9.0% of the outstanding shares of common stock of Xperi sent a letter to Xperi stockholders urging them to replace David Habiger and Darcy Antonellis as members of the Company's Board of Directors with Rubric's nominees, Thomas A. Lacey and Deborah S. Conrad, at Xperi's Annual Meeting of Stockholders, which is scheduled to be held on May 24. In its letter, Rubric underscored Xperi's and its predecessor company's poor total shareholder return under the watch of Mr. Habiger and Ms. Antonellis, and contrasted the superior qualifications, skills, and track records of Mr. Lacey and Ms. Conrad with those of the incumbent directors. The text of letter in part follows: " Rubric Capital Management manages funds and accounts which collectively own approximately 9.0% of the outstanding shares of common stock of Xperi making us the Company's third largest stockholder and largest non-index holder by a wide margin . We have patiently been stockholders of Xperi and its predecessors since Rubric's formation in 2016, but we cannot standby idly any longer while the value of our investment continues to deteriorate.

09:05 EDT Dick's Sporting forms multi-year partnership with Boston Celtics and Red Sox - Dick's Sporting Goods announced partnerships with two legendary professional sports teams based in Boston, the Celtics and Red Sox. These multi-year deals designate DICK'S Sporting Goods as each franchise's Official Sporting Goods Retail Partner, further fostering a connection between the brand and the Boston community. DICK'S partnership with both franchises includes access to tickets and unique fan experiences, as well as IP rights to be used in the new House of Sport store and online within the Boston area. Additionally, signage at TD Garden during certain Celtics home games will include DICK'S House of Sport logo placement in-arena in the form of courtside LED panels, basket stanchions LED panels and center-hung scoreboard LED rings, and specific signage designation at certain games at Fenway Park will include DICK'S House of Sport logo placement at both home and away team bullpens, and behind home plate in-stadium.

09:03 EDT CleanSpark names Scott Garrison COO, Taylor Monnig CTO - CleanSpark appointed Scott Garrison as COO and Taylor Monnig as Chief Technology Officer, or CTO. Garrison was previously SVP of growth and Monnig was previously SVP of mining technology. Before joining CleanSpark in October 2020, Garrison spent the prior three decades of his professional experience leading cross-functional teams. He founded Linq360 and The Integration Center in Las Vegas. In a prior career, he achieved Class A status with the PGA of America. Monnig has developed and led CleanSpark's mining operations teams and the technology that supports them. Prior to CleanSpark, Monnig co-founded TMGCore and served as COO.

08:54 EDT Citi announces minority investment in Cicada Technologies - Citi has made a strategic minority investment in Cicada Technologies. The investment was made by Citi's Markets Strategic Investments unit, which is responsible for the sourcing and execution of strategic investments relevant to Citi's Markets franchise. Citi will also act as a liquidity-provider for the trading platform. Cicada is a fintech based in Greenwich, Connecticut that also has a presence in Mexico. Citi joins existing investors Kaszek Ventures, Dila Capital and BCP Securities.

08:51 EDT Wells Fargo names Fernando Rivas co-CEO of Corporate & Investment Banking - Wells Fargo announced that Fernando Rivas has been named SEVP and co-CEO of Corporate & Investment Banking, or CIB, reporting to Wells Fargo CEO Charlie Scharf and joining the company's operating committee, effective immediately. Rivas and Jon Weiss, who has been CIB's CEO since February 2020, will lead the business together.

08:48 EDT Redwire 3D bioprints 1st live human heart tissue with BFF on ISS - Redwire announced that it has successfully 3D bioprinted the first live human heart tissue sample though its 3D BioFabrication Facility BFF onboard the International Space Station ISS . The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire's PIL-BOX platform..."These are extraordinary scientific achievements that bring us closer to reliable, large-scale commercial biotech services on-orbit," said Redwire In-Space Industries President John Vellinger. "With BFF and PIL-BOX, Redwire has leveraged decades of spaceflight heritage to position itself as a market leader for space biotech capabilities and is now setting the pace for on-orbit contract development and production."

08:45 EDT Cognyte gets approximately $5M additional order from EMEA region - Cognyte Software announced that it received an approximately $5m additional order from a national intelligence organization in the Europe-Middle East-Africa OR EMEA, region, for its solution that helps identify and prevent threats during operations. Including this latest order, Cognyte has received three orders from this customer over the past year, serving as a testament to the superiority of the company's technology. Through ongoing delivery of effective results, Cognyte's solutions enhance operational efficiency and create substantial value for the customer's operational teams.

08:43 EDT Netcapital pursues broker-dealer license to increase revenue - Netcapital announced that its wholly-owned subsidiary, Netcapital Securities , has applied for broker-dealer registration with the Financial Industry Regulatory Authority or FINRA . This marks a significant step in the Company's evolution as it looks to expand upon its current service offerings and support private companies with larger and later stage financings than are currently permitted under Regulation Crowdfunding or "Reg CF. Netcapital believes that by having a registered broker-dealer, it will create opportunities to expand its revenue base by: . Hosting and generating additional fees from Reg A+ and Reg D offerings on the Netcapital platform. Under Reg A+, companies can raise up to $75 million from accredited and non-accredited investors every 12 months versus $5 million permitted under Reg CF . Additionally, under Reg D 506 , companies can raise unlimited amounts of capital from accredited investors using general solicitation.

08:38 EDT Reborn Coffee announces expansion into China market through MLA with IAID - Reborn Coffee announced a significant expansion into the China market through a strategic Master License Agreement, MLA, with IAID. This agreement will introduce a flagship location in Guangzhou #73, situated in a central, historic district bustling with tourists. The site will feature a comprehensive brand center, setting the stage for future expansions into major cities like Shanghai and Shenzhen, China. The joint venture combines Reborn Coffee's experience in retail coffee operations with IAID's expertise in lifestyle design. Together, they aim to revolutionize the coffee culture in China, particularly in the vibrant Guangdong Province, which boasts a population of over 127.06 million. "We are fully dedicated to ensuring our expansion into China becomes a landmark success. This joint venture with IAID Co., Ltd. is a significant step forward in our strategic endeavors to introduce Reborn Coffee's distinctive coffee culture to new geographies," stated Jay Kim, CEO of Reborn Coffee Inc.

08:35 EDT Neurocrine initiates Phase 1 clinical study of NBI-1117567 in healthy adults - Neurocrine Biosciences initiated its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions.

08:34 EDT Southwest Gas sees 2024 CapEx $830M

08:32 EDT Perma-fix commends EPA on regulatory, enforcement measures for PFAS - Perma-Fix Environmental Services applauded the U.S. Environmental Protection Agency, EPA, for setting strict new regulatory and enforcement measures related to per- and polyfluoroalkyl substances, PFAS. The new regulatory measures include: Designation of PFAS as hazardous substances; Issuing a Comprehensive Environmental Response, Compensation, and Liability Act enforcement discretion policy; Finalizing standards to protect people and communities from PFAS contamination in drinking water; Dedicating $9 billion in funding to address PFAS and other emerging contaminants in drinking water and an additional $12 billion in funding to support general drinking water investments, including PFAS treatment.

08:27 EDT Anixa Biosciences enters partnership to develop additional cancer vaccines - Anixa Biosciences has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute. The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine. Researchers are investigating if certain cancer cells can be destroyed as they arise, and ultimately prevent tumors from forming. The vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the company.

08:18 EDT Foresight Autonomous leverages Nvidia Jetson Orin to introduce new solution - Foresight Autonomous (FRSX) has announced a major breakthrough with the development of Dragonfly Vision, its cutting-edge 360-degrees 3D perception solution, based on the NVIDIA (NVDA) Jetson AGX Orin platform, designed for power-optimized autonomous machines. By using the NVIDIA Jetson AGX Orin platform, Foresight can create an all-around obstacle detection solution, including the detection of non-classified objects. The NVIDIA Jetson AGX Orin module supports up to six stereo channels to achieve complete coverage around any type of vehicle.

08:15 EDT LGI Homes announces second community in Modesto market - LGI Homes announced the opening of its second community in the Modesto, California, market, Diamond Bar East. This community offers a variety of one and two-story homes and is located northeast of Modesto in the town of Riverbank. "We are excited to be a part of the tremendous growth here in Riverbank. Diamond Bar East is so close to everything and offers an easy commute to the Bay Area. However, you don't need to go anywhere because everything you need is just five to ten minutes away. Diamond Bar East is a real gem!" said Jeanine Roach, Vice President of Sales for LGI Homes.

08:13 EDT Horizon Aircraft provides update on technical flight testing progress - New Horizon Aircraft announced several updates as the Company continues to prove critical technology elements of its unique aircraft. Brandon Robinson, Chairman and Chief Executive Officer of Horizon commented, "The extremely positive test results continue to validate our innovative technology, our practical approach, and the team's capability to deliver on our target timeline." Robinson continued, "Over the past several months, Horizon has made incredible progress. I am continually amazed with the technical aptitude of our team as it clears one engineering hurdle after another. The transition flight testing program has taken significant strides forward, with the aircraft demonstrating impressive stability and control all the way from hover to approaching transition speeds."

08:12 EDT ProQR Therapeutics announces preclinical proof of concept data for AX-0810 - ProQR Therapeutics announced new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical proof of concept data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP. The data are being presented at a poster session today at the American Society of Gene & Cell Therapy Annual Meeting, May 7-11, 2024, in Baltimore, Maryland. Data presented include: Axiomer EONs can specifically modulate NTCP protein bile acids reuptake function while preserving expression of the protein. A strong correlation was reported between editing levels of NTCP and bile acids change in the serum in NHP in vivo. An early generation of ProQR's Axiomer editing oligonucleotides, EON1, yielded up to 29% editing of NTCP in the liver of non-human primates after a single dose and, importantly, this led to an 8-fold change in the serum biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled achievement of up to 60% editing. Results reported in NHPs confirmed findings in in vitro models and showed translatability across models. ProQR also expects the following Axiomer pipeline program milestones in 2024: AX-0810 clinical development candidate translational data to be reported in H2 2024, with further detail on design for the clinical trial. AX-1412 preclinical proof of concept data and translational data to be reported in H2 2024, with program to advance to the clinic in late 2024/early 2025. AX-1412 is the company's Axiomer program targeting B4GALT1 for cardiovascular disease.

08:11 EDT Nikola opens second HYLA high-pressure refueling station in Southern California - Nikola announced the opening of its latest HYLA high-pressure modular refueling station and facility in Southern Calif. Situated near the Port of Long Beach, this new station commenced operations on May 4. This launch is a milestone in Nikola's strategic plan, aiming to establish a network of up to nine refueling solutions by mid-2024, with a total of 14 operational sites slated for completion by year-end. The HYLA refueling network plans to offer a diverse portfolio of refueling solutions to Nikola's hydrogen fuel cell electric vehicles and other Class 8 customers.

08:10 EDT Uber says off to 'solid start' in FY24 - Says making "good progress" on many initiatives. Sees similar trends in Q2 from Q1. Says demand for products "remains strong." Says "exactly where we want to be" vs. 3-year CAGR outlook given in February. Comments taken from Q1 earnings conference call.

08:07 EDT Fulcrum announces publication of results on Phase 2b trial of losmapimod - Fulcrum Therapeutics announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy, FSHD. The data are published in the peer-reviewed journal The Lancet Neurology. While the primary endpoint of change in DUX4-driven gene expression in muscle biopsies did not show significant differences between the treatment and placebo groups, losmapimod was associated with improvements in structural and functional outcomes, including muscle fat infiltration and reachable workspace - a measure of shoulder girdle function, and patient-reported global impression of change when compared to placebo. Losmapimod was also found to be well tolerated by trial participants. No serious adverse events related to the drug were reported, and there were no discontinuations of treatment due to adverse events.

08:04 EDT Acumen announces first patient dosed in ALTITUDE-AD study - Acumen Pharmaceuticals announced that the first patient has been dosed with sabirnetug in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD. "Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

08:01 EDT Alight CFO Katie Rooney to step down, Jeremy Heaton to succeed - Alight announced two leadership promotions as part of the company's ongoing transformation. Jeremy Heaton, who has been with the company for four years most recently serving as operating CFO, will assume the role of CFO, effective immediately. Heaton brings more than two decades of financial experience, including more than 20 years at GE in global financial management. Katie Rooney will step down from her position as global CFO after over 15 years of distinguished service with the company, and will continue in her role as COO supporting the Payroll & Professional Services divestiture until close of the transaction anticipated to be mid-year 2024, after which she will step down.

07:55 EDT Intel: U.S. Department of Commerce revoking some licenses for exports

07:42 EDT Carisma Therapeutics presents data for macrophages in liver fibrosis - Carisma Therapeutics announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treatment of liver fibrosis. The data was presented in a poster session at the American Society of Gene and Cell Therapy 2024 Annual Meeting on May 8 in Baltimore. The data demonstrate that engineered macrophages trafficked to fibrotic tissues expressed genetically encoded disease-modifying payloads, and significantly reduced fibrosis in the liver. The data showed that a single dose of macrophages co-expressing the anti-fibrotic factor relaxin and the anti-inflammatory cytokine IL10 significantly improved established fibrosis in a CCl4-induced liver fibrosis model, with a 116% reduction in fibrosis relative to untreated control. Also, systemic administration of engineered macrophages co-expressing relaxin and IL10 significantly reduced liver fibrosis in a high fat diet MASH model, with a 45% reduction in fibrosis relative to untreated control. Carisma expects to nominate a development candidate for its liver fibrosis program in 1Q25.

07:39 EDT MasterCraft Boat: Revised guidance reflects planned decrease in production

07:36 EDT Cytokinetics announces study of CK-4021586 met primary, secondary objectives - Cytokinetics, Incorporated announced topline data from the Phase 1 study of CK-4021586. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses of CK-586. The data support the advancement of CK-586 to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction which is expected to begin in Q4 2024. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with HFpEF. Phase 1 Design and Key Findings: The primary objective of this Phase 1 double-blind randomized, placebo-controlled, multi-part single and multiple ascending dose clinical study was to evaluate the safety, tolerability and PK of CK-586 when administered orally as single or multiple doses to healthy participants. The study met the primary objective, demonstrating that CK-586 was safe and well tolerated in healthy participants with linear PK. Pharmacodynamics were evaluated using echocardiography and consistent with expectations. No serious adverse events were observed, and the stopping criteria were not met in the study.

07:35 EDT Cytokinetics announces start of CEDAR-HCM trial of aficamten - Cytokinetics, Incorporated announced that CEDAR-HCM, Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM, a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy, HCM, is open to enrollment. "We are pleased to further expand the broad development program for aficamten with the start of CEDAR-HCM, a trial assessing the safety and efficacy of a cardiac myosin inhibitor in a pediatric population," said Fady Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development.

07:33 EDT Alterity announces DMC recommends to continue Phase 2 study of ATH434-201 - Alterity Therapeutics announced that an independent Data Monitoring Committee, DMC, has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy, MSA, a rare neurodegenerative disease with no approved treatments to slow or stop its progression. "We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned," said David Stamler, M.D., Chief Executive Officer of Alterity. "This recommendation is important as ATH434 continues to demonstrate a favorable safety profile with long term exposure. The trial remains on track to complete in November 2024 and report top-line data in January 2025."

07:30 EDT WTW announces strategic enhancements to its global cyber facility - WTW announces strategic enhancements to its global cyber facility. Following a successful launch in January 2023, WTW's CyXS facility, a global solution for excess cyber insurance coverage, has introduced new features, effective 1 April 2024, designed to meet the dynamic needs of clients and keep ahead of market trends as cyber risks escalate.

07:28 EDT Inception Growth Acquisition announces contribution to Trust Account - Inception Growth Acquisition announces that on May 6, 2024, the Company deposited $100,000 into the Company's trust account in order to extend the period of time the Company has to complete a business combination for an additional one month period, from May 13, 2024 to June 13, 2024. The purpose of the extension is to provide additional time for the Company to complete a business combination.

07:26 EDT Multi Ways Holdings expands fleet with acquisition of 16 new crawler cranes - Multi Ways Holdings announces its procurement contract to acquire 16 new crawler cranes, further strengthening its fleet, with deliveries expected throughout the remainder of 2024. James Lim, Chairman and CEO of Multi Ways, commented on the acquisition, stating, "We are excited to announce the expansion of our fleet with the acquisition of these 16 new crawler cranes. This strategic move reflects our dedication to meeting the evolving needs of our customers and strengthening our position in the market. With the construction sector showing positive growth and significant infrastructure projects underway, this investment comes strategically, allowing us to serve our clients better and capitalize on market opportunities."

07:25 EDT Chemomab Therapeutics granted 180-day extension to regain Nasdaq compliance - Chemomab Therapeutics Ltd. announced that it received formal notification from the Listing Qualification Department of the Nasdaq Stock Market notifying the company that it has been granted an additional 180-day compliance period, or until November 4, 2024, to regain compliance with Nasdaq's minimum $1.00 bid price per share requirement. If at any time until November 4, 2024, the closing bid price of Chemomab's American Depositary Shares is at least $1.00 per ADS for a minimum of 10 consecutive trading days, Nasdaq will provide written confirmation of compliance to the company and the matter will be closed.

07:20 EDT Omega Therapeutics presents new preclinical data at ASGCT 2024 - Omega Therapeutics announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy, ASGCT, 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 - 11. "These exciting new data underscore the versatile capabilities and power of our OMEGA platform," said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. "We have demonstrated preclinically that we can prospectively engineer epigenomic controllers to predictably and durably upregulate gene expression across a diverse range of gene types, including turning on inactivated genes, augmenting the expression of genes with low baseline expression levels, and leveraging existing genomic regulatory processes to boost expression. These capabilities unlock a wide spectrum of possibilities to apply precision epigenomic control as a novel therapeutic modality to meaningfully address key drivers of many diseases."

07:14 EDT Zevra Therapeutics sees cash, equivalents extending cash runway into 2026 - The company's cash runway forecast includes revenue from the expected sales of OLPRUVA, ongoing reimbursements from the French EAP for arimoclomol, ongoing royalties under the AZSTARYS license agreement, investments into the incremental commercial activities needed to support the launch of arimoclomol, if approved, and completion of the KP1077 development program for IH. The company's cash runway forecast does not include any commercial revenue from arimoclomol which could follow a potential FDA approval, or the potential sale of the Priority Review Voucher which would be received upon approval.

07:12 EDT Canadian Solar wins three BESS projects in Japan totaling 193 MW - Canadian Solar announced that it has won three battery energy storage system projects, totaling 193 MW, in Japan's first Long-Term Decarbonization Power Source Auction. The winners of this auction were announced on April 26, 2024, with the Company securing a 13.3% of the total awarded energy storage projects. Canadian Solar will enter into Capacity Reserve Agreements with the Organization for Cross-regional Coordination of Transmission Operators. These energy storage projects will provide capacity over a 20-year period, in return for Capacity Reserve Payments to offset fixed storage system costs. Located in Aomori, Fukushima, and Yamaguchi prefectures respectively, the three projects are expected to commence commercial operations between 2027 to 2028 and will feature the recently launched SolBank 3.0 system from e-STORAGE, a subsidiary CSI Solar Co., Ltd.

07:06 EDT Trimble acquires Flashtract, terms undisclosed - Trimble announced it has acquired privately-held Flashtract, a company delivering specialized technology to streamline the flow of payment and compliance information between construction general contractors and subcontractors. Financial terms were not disclosed.

07:05 EDT NexGen Energy purchases 2,702,410 pounds of natural uranium concentrate - NexGen Energy announced that it has entered into a binding term sheet with MMCap International for the purchase of 2,702,410 pounds natural uranium concentrate for an aggregate purchase price of $250M based on the five-day average UxC spot price. In satisfaction of the purchase price for the U3O8, the company has agreed to issue $250M aggregate principal amount of unsecured convertible debentures. The debentures will be convertible at the holder's option into approximately 23M common shares of NexGen equivalent to 4.3% of the company's issued and outstanding common shares. Upon closing of the previously announced Australian Chess Depository Interest offering, as well as this transaction with MMCap, the company will have C$600M in cash and $250M worth of physical uranium on its balance sheet.

06:58 EDT Aecom joint venture to deliver the UK National Grid's Great Grid upgrade - Aecom's joint venture with Arup has been appointed as a design and consenting service partner for the UK National Grid's Great Grid Partnership. The Partnership is expected to deliver a design and construction program to connect clean energy to homes and businesses throughout England and Wales by 2030, playing a critical role in the UK's energy transition. The joint venture's scope of work will include delivering the consents for individual schemes within the program. These consents will be through Development Consent Orders which entail technical and environmental design and preparation, as well as stakeholder engagement on the plans.

06:48 EDT Compass Pathways sees Q2 net cash burn $32M-$38M - Sees FY24 net cash burn $110M-$130M. Cash position at March 31, 2024, is expected to be sufficient to fund operating expenses and capital expenditure requirements into 2026.

06:42 EDT Compass Pathways' COMP360 psilocybin meets Phase 2 safety endpoint in PTSD - Compass Pathways announced top-line results from an open-label phase 2 study evaluating the safety and tolerability of investigational COMP360 psilocybin treatment in 22 patients with post-traumatic stress disorder, or PTSD. The study met its primary safety endpoint and available secondary efficacy endpoints. Study observations included meaningful and sustained symptom improvement from baseline in a measure of disease severity, and in a measure of functional impairment in daily life. Administration of COMP360 was well-tolerated, with a safety profile consistent with previous studies. Administration was well tolerated, with no serious adverse events observed. There were no treatment-emergent serious adverse events. Durable improvement in symptoms from baseline observed following a single administration. High and sustained rates of response and remission relative to baseline, with early onset of symptom improvement. No patients withdrew from the study and no patients returned to antidepressant medication treatment during the trial.

06:36 EDT Teva, Medincell report 'positive' results from Phase 3 trial of TEV-'749 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study trial evaluating TEV-'749 in adult patients with schizophrenia compared to placebo. Results demonstrated that TEV-'749 met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo. TEV-'749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled steady release of olanzapine, the most prescribed 2nd generation antipsychotic for schizophrenia in the U.S. TEV-'749 met its primary endpoint across all three dosing groups, with mean difference in change in the Positive and Negative Syndrome Scale total score from baseline to week 8 of -9.71 points, -11.27 points, and -9.71 points versus placebo for the high, medium, and low dose groups, respectively. These differences from placebo were clinically meaningful and statistically significant with adjusted P-values of for each comparison. Key secondary endpoints of CGI-S and PSP total score were also statistically significant after adjusting for multiplicity. No cases of PDSS have been reported to date, after administration of approximately 80% of the target injection number.

06:32 EDT Avidity gets FDA Breakthrough Therapy designation for delpacibart etedesiran - Avidity Biosciences announced that the FDA has granted Breakthrough Therapy designation to delpacibart etedesiran, the company's lead clinical development program, for the treatment of myotonic dystrophy type 1. Delpacibart etedesiran, abbreviated as del-desiran, is an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies.

06:17 EDT Shell to sell interest in Singapore Energy and Chemicals Park to CAPGC - Shell Singapore Pte Ltd, a subsidiary of Shell plc, has reached an agreement to sell its Energy and Chemicals Park in Singapore to CAPGC Pte. Ltd., a joint venture company between Chandra Asri Capital Pte. Ltd. and Glencore Asian Holdings Pte. Ltd. The transaction will transfer all of Shell's interest in Shell Energy and Chemicals Park Singapore to CAPGC. "This agreement marks a significant step in Shell's ongoing efforts to high-grade our Chemicals and Products business, and is a testament to our commitment to deliver more value with less emissions, as outlined at our Capital Markets Day last year." said Huibert Vigeveno, Shell's Downstream, Renewable and Energy Solutions Director. "We are proud of our history at Bukom and Jurong Island and our contributions to the economic growth of Singapore in this sector in the past decades. Our commitment to Singapore remains steadfast and its importance as a regional hub for our marketing and trading business remains important. As Singapore continues to decarbonise, Shell looks forward to a continued partnership with the country, and with our customers in the region." Shell ran a competitive bid process to reach this milestone. Staff in Shell Energy and Chemicals Park Singapore will continue their employment with CAPGC under the new ownership, providing continuity for staff and contributing to ongoing operational reliability and safety, the company stated. Subject to regulatory approval, the transaction is expected to complete by the end of 2024.

06:15 EDT Occidental Petroleum sees Q2 total production 1,232-1,272 Mboed - Comments taken from Q1 earnings conference call presentation slides.

06:11 EDT Regeneron reports positive results from DB-OTO study - Regeneron Pharmaceuticals announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment. Both children were born with profound genetic deafness due to variants of the otoferlin gene, and the child dosed at 11 months of age is one of the youngest in the world to receive a gene therapy for genetic deafness. The results are from the ongoing Phase 1/2 CHORD trial, which is currently enrolling infants and children and were detailed during an oral presentation at the American Society of Gene and Cell Therapy annual conference.

05:09 EDT Elbit Systems awarded $53M contract - Elbit Systems announced that it was awarded a contract worth approximately $53M to supply the Crossbow Unmanned Turreted 120mm Soft Recoil Mortar Systems to General Dynamics European Land Systems, or GDELS, for the installation on Pandur 6x6 APC wheeled armored vehicle for a European customer. The contract will be performed over a period of 6 years.